---

1. At a Glance – Blink and You’ll Miss the Plot Twist

Jagsonpal Pharmaceuticals Ltd is that old-school Indian pharma uncle who suddenly learned Instagram Reels and started flexing. Founded in 1978, ignored for decades, and now casually sitting at a market cap of ₹1,088 crore while retail investors argue whether this is “already expensive” or “still undiscovered”.

Current price? ₹164, which is closer to its 52-week low of ₹161 than the euphoric ₹302 peak. Translation: the stock market recently ghosted it.
3-month return: –24.7%, 6-month return: –37.6%. Ouch.
But fundamentals? Those didn’t get the memo.

Latest Q3 FY26 results (Quarterly Results – lock applied 🔒) show:

• Revenue: ₹729 mn
• PAT: ₹110 mn
• Operating Margin: ~22%
• Debt-to-equity: a saintly 0.03

ROCE at 23%, ROE at 18.6%, dividend yield 1.52%, and interest coverage so high (55x) that lenders feel emotionally neglected.

So what’s happening here? Is the market throwing a tantrum while the company quietly compounds? Or is there something cooking under the lab coat?

Let’s dissect this pharma patient — without anaesthesia.

---

2. Introduction – 45-Year-Old Pharma, Midlife Crisis Cancelled

Jagsonpal is not a startup pretending to be a platform. It’s a 45-year-old pharma formulation company that survived price controls, DPCO nightmares, distributor drama, and FDA paperwork hell.

Its sweet spot?
👉 Women-centric healthcare — gynaecology and orthopaedics — which in Indian pharma is like owning a busy chai tapri near a railway station. Demand doesn’t disappear.

Add to that:

• Antibiotics
• Pediatrics
• Dermatology
• Immunity & OTC

Basically, if a doctor can write it in slightly unreadable handwriting, Jagsonpal probably sells it.

The company runs an asset-light model by fully outsourcing manufacturing via loan licensing. No giant factories. No chest-thumping capex stories. Just formulations, branding, and distribution.

And distribution is where Jagsonpal flexes:

• 900+ sales reps
• Pan-India presence
• 17 brands ranked in the Top 5 of their molecule categories
• Top 5 brands contribute ~47% of revenue, Top 7 ~67%

Question for you:
Is this concentration risk… or proof that doctors actually trust these brands?

---

3. Business Model – WTF Do They Even Do?

Jagsonpal’s business model is best explained as:

“We don’t manufacture drama. We manufacture prescriptions.”

Step-by-step:

1. Product selection: Focus on chronic and repeat-use therapies (gynae, ortho, pediatrics).
2. Outsourced manufacturing: Vendors manufacture; Jagsonpal supplies raw material.
3. Branding & marketing: Doctors remember brands, not factories.
4. Sales muscle: 900+ reps knocking clinic doors daily.
5. Cash collection: Debtor days down to 18 days — which in pharma is Olympic-level discipline.

Because manufacturing is outsourced:

• Capital employed stays low
• ROCE stays high
• Fixed asset risk stays minimal

This is why despite modest sales growth, profit growth has been explosive.

But wait — Jagsonpal didn’t just chill. It went shopping.

---

4. Financials Overview – Numbers That Actually Matter

Quarterly Comparison Table (₹ crore)

Metric	Latest Qtr (Q3 FY26)	YoY Qtr (Q3 FY25)	Prev Qtr (Q2 FY26)	YoY %	QoQ %
Revenue	72.9	74.0	74.0	-1.5%	-1.5%
EBITDA	16.0	16.0	16.0	~0%	~0%
PAT	11.0	32.0*	13.0	-65.6%	-15.4%
EPS (₹)	1.64	4.82*	1.89	-66%	-13%

*YoY PAT and EPS were inflated due to unusually high other income in Q3 FY25.

EPS Annualisation (Rule Applied)

• Latest quarterly EPS: ₹1.64
• Annualised EPS = 1.64 × 4 = ₹6.56

So at ₹164, P/E ≈ 25, broadly matching reported numbers.

Sarcastic takeaway:

Revenue flat, margins fat, profits normalized. This is not collapse — this is digestion after acquisition binge.

Would you rather see volatile revenue or stable margins?

---

5. Valuation Discussion – Let’s Be Boring and Accurate

Method 1: P/E Multiple

• Annualised EPS: ₹6.56
• Conservative pharma multiple: 22–28x

👉 Value Range: ₹144 – ₹184

Method 2: